Caxton Associates LP Acquires Shares of 600 Regeneron Pharmaceuticals, Inc. (REGN)

Caxton Associates LP acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 600 shares of the biopharmaceutical company’s stock, valued at approximately $268,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. IFP Advisors Inc increased its holdings in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares in the last quarter. Global X Management Co. LLC increased its holdings in Regeneron Pharmaceuticals by 43.8% in the second quarter. Global X Management Co. LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 367 shares in the last quarter. National Planning Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $215,000. Advisors Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 45.2% in the second quarter. Advisors Asset Management Inc. now owns 7,700 shares of the biopharmaceutical company’s stock valued at $3,782,000 after buying an additional 2,396 shares in the last quarter. Finally, Dupont Capital Management Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $220,000. 66.67% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals, Inc. (REGN) opened at $383.12 on Friday. The firm has a market cap of $41,011.62, a PE ratio of 33.05, a P/E/G ratio of 1.50 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the business posted $3.13 earnings per share. analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

REGN has been the subject of a number of recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Citigroup reiterated a “buy” rating and issued a $575.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. UBS dropped their target price on shares of Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, September 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $465.40.

In related news, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Caxton Associates LP Acquires Shares of 600 Regeneron Pharmaceuticals, Inc. (REGN)” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://weekherald.com/2017/12/15/caxton-associates-lp-acquires-shares-of-600-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply